ARTESiA
2024
Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Subclinical Atrial Fibrillation
In 4,012 patients with device-detected subclinical AF and stroke risk factors, apixaban reduced stroke or systemic embolism compared with aspirin, at the cost of more bleeding.
Result
Efficacy: Stroke or systemic embolismHR 0.63 (95% CI 0.45-0.88) · P = 0.007
Safety: Major bleedingHR 1.80 (95% CI 1.26-2.57)
Below 1 favours apixaban, above 1 favours aspirin.
Event rates Apixaban 0.78 vs aspirin 1.24 per 100 patient-years (stroke or systemic embolism)
- Subtopic
- DOAC
- Design
- Double-blind, double-dummy RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2024 AF
- Source
- Healey JS, et al. N Engl J Med. 2024;390(2):107-117.doi 10.1056/NEJMoa2310234
Discussion & critique
Absolute stroke reduction was small (~0.4%/yr) and offset by increased major bleeding, so anticoagulation for subclinical AF demands individualised risk-benefit weighing. With NOAH-AFNET 6 tempered enthusiasm for routine anticoagulation of brief device-detected AF.